Good morning :)
Place Order
Add to Watchlist

Alembic Pharmaceuticals Ltd

APLLTD Share Price

849.650.03% (-0.25)

APLLTD Share Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹16,700 cr, stock is ranked 370
Moderate RiskStock is 2.68x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹16,700 cr, stock is ranked 370
Moderate RiskStock is 2.68x as volatile as Nifty

APLLTD Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
27.623.471.29%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.796.340.53%

APLLTD Analyst Ratings & Forecast

Detailed Forecast 
50%
Analysts have suggested that investors can buy this stock

from 10 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

APLLTD Company Profile

Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).

Investor Presentation

View older 

Feb 3, 2025

PDF
View Older Presentations

APLLTD Similar Stocks (Peers)

Compare with peers 
PE Ratio
43.72
1Y Return
13.30%
Buy Reco %
88.24
PE Ratio
29.61
1Y Return
11.53%
Buy Reco %
72.73
PE Ratio
66.50
1Y Return
25.57%
Buy Reco %
68.00
PE Ratio
55.83
1Y Return
10.60%
Buy Reco %
81.25
PE Ratio
17.56
1Y Return
2.15%
Buy Reco %
46.67
Compare with Peers
APLLTD Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

APLLTD Stock Summary · November 2024

Alembic Pharmaceuticals demonstrated a modest 3% revenue growth in Q2 FY '25, buoyed by strong EBITDA and net profit, despite facing significant challenges in its API segment, which saw a 15% decline due to pricing pressures and competition. Management remains optimistic about recovery, anticipating a boost from approximately 10 new product launches in the second half of the fiscal year, particularly in the U.S. market. However, growth in the Specialty and Acute segments has slowed, necessitating a 15% increase in the latter half to meet annual targets. Financially, the company is grappling with negative operating cash flow and rising debt levels, yet it aims to stabilize these metrics as working capital is consumed. Additionally, strategic entry into the GLP-1 market reflects a proactive approach to capitalize on emerging opportunities, underscoring a commitment to enhancing productivity and maintaining market share amidst ongoing challenges.

Key Points on Aplltd Stock
APLLTD Stock Growth Drivers
6
  • Strong Financial Performance

    Alembic Pharmaceuticals reported a 3% increase in total revenue, reaching INR 1,648 crores, with EBITDA

  • Successful Product Launches and Regulatory Approvals

    The company launched eight products in the U.S. during the quarter and achieved nine approvals,

APLLTD Stock Challenges
6
  • Decline in API Business Performance

    Alembic Pharmaceuticals Limited has reported a 15% decline in its API business, primarily due to

  • Ongoing Pricing Pressures

    The company is facing consistent pricing pressures in the U.S. market, characterized by high single-digit

APLLTD Forecasts

Price

Revenue

Earnings

APLLTD

Income

Balance Sheet

Cash Flow

APLLTD Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.67%, vs industry avg of 9.04%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.8% to 1.64%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 1.05%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue3,173.113,107.173,137.843,944.064,610.695,480.425,361.535,655.366,256.936,465.78
Raw Materialssubtract877.07928.05927.621,084.971,249.981,451.271,489.611,630.171,857.925,423.44
Power & Fuel Costsubtract58.8964.2070.3588.86102.40118.72120.84151.54173.37
Employee Costsubtract472.85558.83622.81746.69906.441,051.171,133.001,169.131,446.29
Selling & Administrative Expensessubtract507.40791.13700.51961.11913.651,104.031,354.871,474.001,543.70
Operating & Other expensessubtract243.09147.67166.42179.47253.92187.65333.31550.33274.96
Depreciation/Amortizationsubtract72.2182.97105.46115.23157.32183.48286.78275.43272.67279.07
Interest & Other Itemssubtract5.435.233.4018.4127.1616.0217.7350.1756.1965.19
Taxes & Other Itemssubtract216.12125.93128.64164.95171.00221.58104.4512.6016.0193.33
EPS38.2021.3921.8931.0043.9759.5526.5017.4031.3330.77
DPS3.504.004.005.5010.0014.0010.008.0011.0011.00
Payout ratio0.090.190.180.180.230.240.380.460.350.36

APLLTD Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2016

Annual report

PDF

Investor Presentation

Jan 21PDF
FY 2017

Annual report

PDF

Investor Presentation

Jul 29PDF
FY 2023

Annual report

PDF

Investor Presentation

May 5PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 4PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 3PDF
Nov 7PDF
 

APLLTD Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alembic Pharmaceuticals Ltd27.123.471.29%
Sun Pharmaceutical Industries Ltd43.726.240.77%
Cipla Ltd29.614.550.86%
Torrent Pharmaceuticals Ltd66.5016.070.86%

APLLTD Stock Price Comparison

Compare APLLTD with any stock or ETF
Compare APLLTD with any stock or ETF
APLLTD
Loading...

APLLTD Shareholdings

APLLTD Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

APLLTD Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

APLLTD Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding69.67%9.20%7.23%3.94%9.96%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

APLLTD Shareholding History

Dec '23MarJunSepDec '24Mar4.52%4.46%4.32%3.94%4.17%3.94%

Mutual Funds Invested in APLLTD

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.9123%2.03%-0.03%50/81 (-2)
1.6519%1.60%-0.04%26/61 (+1)
0.8066%0.59%-0.03%85/137 (0)

Compare 3-month MF holding change on Screener

APLLTD Insider Trades & Bulk Stock Deals

Loading...

smallcases containing APLLTD stock

Looks like this stock is not in any smallcase yet.

APLLTD Events

APLLTD Dividend Trend

No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

APLLTD has shown inconsistent dividend trend over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.30%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹12.97 every year

Dividends

Corp. Actions

Announcements

Legal Orders

APLLTD Upcoming Dividends

No upcoming dividends are available

APLLTD Past Dividends

Cash Dividend

Ex DateEx DateJul 15, 2024

Final
Final | Div/Share: ₹11.00

Dividend/Share

11.00

Ex DateEx Date

Jul 15, 2024

Cash Dividend

Ex DateEx DateJul 28, 2023

Final
Final | Div/Share: ₹8.00

Dividend/Share

8.00

Ex DateEx Date

Jul 28, 2023

Cash Dividend

Ex DateEx DateAug 17, 2022

Interim
Interim | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Aug 17, 2022

Cash Dividend

Ex DateEx DateJul 19, 2021

Final
Final | Div/Share: ₹14.00

Dividend/Share

14.00

Ex DateEx Date

Jul 19, 2021

Cash Dividend

Ex DateEx DateMar 16, 2020

Interim
Interim | Div/Share: ₹7.00

Dividend/Share

7.00

Ex DateEx Date

Mar 16, 2020

APLLTD Stock News & Opinions

Corporate
Alembic Pharmaceuticals to conduct board meeting

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 May 2025.Powered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Alembic Pharma receives final approval for Carbamazepine tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tegretol Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. Carbamazepine Tablets USP, 200 mg, are indicated for use as an anticonvulsant drug. They are also indicated for the treatment of pain associated with true trigeminal neuralgia. Refer to the product label for the complete list of indications. Carbamazepine Tablets USP, 200 mg, have an estimated market size of US$ 32 million for the twelve months ending December 2024, according to IQVIA. With this approval, Alembic now has a cumulative total of 222 ANDA approvals from the USFDA, comprising 196 final approvals and 26 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company that has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. The company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24. Revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY). Shares of Alembic Pharmaceuticals shed 0.19% to Rs 850.15 on the BSE.Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
Alembic Pharmaceuticals receives USFDA approval for Carbamazepine Tablets

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tegretol Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. Carbamazepine Tablets USP, 200 mg are indicated for use as an anticonvulsant drug. It is also indicated in the treatment of the pain associated with true trigeminal neuralgia. Refer label for a detailed indication. Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA. Alembic has a cumulative total of 222 ANDA approvals (196 final approvals and 26 tentative approvals) from USFDA.Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
Alembic Pharmaceuticals receives USFDA approval for Pantoprazole sodium for injection

Alembic Pharmaceuticals has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDAPantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Protonix I.V. for Injection, 40 mg/vial, of Wyeth Pharmaceuticals LLC. Pantoprazole sodium for injection is indicated for treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. It is also indicated for the treatment of pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome in adults.  Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Alembic Pharma receives USFDA final approval for Pantoprazole Sodium Injection

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Protonix I.V. for Injection, of Wyeth Pharmaceuticals LLC. Pantoprazole sodium for injection is indicated for the treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults. It is also indicated for the treatment of pathological hypersecretion conditions, including Zollinger-Ellison (ZE) syndrome in adults. Refer to the label for a detailed indication. According to IQVIA, the estimated market size for pantoprazole sodium for injection was US$ 48 million for the twelve months ending December 2024. With this approval, Alembic has a cumulative total of 221 ANDA approvals from the USFDA, including 195 final approvals and 26 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. The company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24. Revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY). The counter slipped 2.66% to end at Rs 904.55 on the BSE. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Live Market Update
Indices drift higher in early trade; breadth strong

The key equity benchmarks traded with major gains in early trade. The Nifty traded above 23,500 level. Realty, oil &gas and PSU bank advanced while IT and Auto shares declined. At 09:26 IST, the barometer index, the S&P BSE Sensex, added 524.12 points or 0.68% to 77,429.63. The Nifty 50 index advanced 153.30 points or 0.66% to 23,503.70. The broader market broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.80% and the S&P BSE Small-Cap index added 0.99%. The market breadth was strong. On the BSE, 2,612 shares rose and 590 shares fell. A total of 151 shares were unchanged. Foreign portfolio investors (FPIs) bought shares worth Rs 7,470.36 crore, while domestic institutional investors (DIIs) were net sellers to the tune of Rs 3,202.26 crore in the Indian equity market on 21 March 2025, provisional data showed. Stocks in Spotlight: Alembic Pharmaceuticals declined 2.10%. The company said that its API'III facility located at Karakhadi, Gujarat, has successfully cleared the US Food and Drug Administration (USFDA) inspection with zero observations. Larsen & Toubro (L&T) added 2.44% after the company announced that Subramanian Sarma will be elevated from whole-time director & president, Energy to deputy managing director (MD) & president of the company with effect from 2nd April 2025. Meanwhile, the company's board approved long term borrowings of upto Rs 12,000 crore, including through external commercial borrowings, term loans, non-convertible debentures or any other instrument as may be appropriate. Reliance Industries advanced 1.02% after the company said that its step-down wholly owned subsidiary Nauyaan Tradings has completed the acquisition of 74% equity stake in Nauyaan Shipyard (NSPL), from Welspun Corp, for an aggregate consideration of Rs 382.73 crore. Numbers to Track: The yield on India's 10-year benchmark federal paper advanced 1.66% to 6.737 as compared with the previous close of 6.620. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 85.8975, compared with its close of 85.9800 during the previous trading session. MCX Gold futures for the 4 April 2025 settlement shed 0.06% to Rs 87,737. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.04% to 104.13. The United States 10-year bond yield rose 0.47% to 4.272. In the commodities market, Brent crude for May 2025 settlement advanced 17 cents or 0.24% to $72.17 a barrel. Global Markets: US Dow Jones index futures rose 217 points, signaling a strong opening for US stocks today. Media reports suggest that President Donald Trump's April 2 tariffs will be narrower and less stringent than initially feared, easing concerns about their economic impact. Asian stocks traded mixed on Monday as investors braced for Trump's looming April 2 tariff deadline. In Japan, business activity shrank for the first time in five months. The au Jibun Bank Manufacturing PMI fell to 48.3 in March, down from 49.0 in February, marking its ninth consecutive month of contraction. Meanwhile, the Services PMI dropped to 49.5 from 53.7, the first decline since mid-2024. A PMI reading below 50 indicates contraction. Meanwhile, Chinese Premier Li Qiang warned of 'rising instability' and urged nations to open up their markets. On Friday, US market closed higher as Trump hinted at flexibility on tariffs, although he reaffirmed the April 2 deadline for reciprocal duties. The S&P 500 rose 0.08% to 5,667.56 points, while the NASDAQ Composite rose 0.52% to 17,784.05 points. The Dow Jones Industrial Average rose 0.08% to 41,985.35 points. Nike stock slipped over 5% after fiscal fourth-quarter revenue estimate came in below analysts' expectations. While stocks have rebounded from oversold levels, investors remain cautious. Until there is clarity on the tariff situation'expected by April 2'the market's upside potential will likely remain limited.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Stock Alert: Alembic Pharma, L&T, RIL, M&M, Godrej Properties

Securities in F&O Ban: Hindustan Copper, IndusInd Bank and Polycab India shares are banned from F&O trading on 24th March 2025 Stocks to Watch: Alembic Pharmaceuticals said that its API'III facility located at Karakhadi, Gujarat, has successfully cleared the US Food and Drug Administration (USFDA) inspection with zero observations. Larsen & Toubro (L&T) announced that Subramanian Sarma will be elevated from whole-time director & president, Energy to deputy managing director (MD) & president of the company with effect from 2nd April 2025. Meanwhile, the company's board approved long term borrowings of upto Rs 12,000 crore, including through external commercial borrowings, term loans, non-convertible debentures or any other instrument as may be appropriate. Reliance Industries said that its step-down wholly owned subsidiary Nauyaan Tradings has completed the acquisition of 74% equity stake in Nauyaan Shipyard (NSPL), from Welspun Corp, for an aggregate consideration of Rs 382.73 crore. Mahindra & Mahindra (M&M) announced an increase in prices of up to 3% for its SUV and CV range, effective April 2025. This price increase is attributed to rising input cost and increased commodity prices, among other reasons. Godrej Properties (GPL) announced the acquisition of approximately 10 acres of land in Yelahanka, Bengaluru, for a new development project with an estimated revenue potential of Rs 2,500 crore. SMS Pharmaceuticals announced that it has successfully completed a US Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility located in Bachupally, Hyderabad, Telangana. The inspection was conducted from 17 March to 21 March 2025 and concluded with one observation in Form 483. Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
Alembic Pharma's Gujarat facility clears USFDA inspection

The inspection was conducted from 17th March to 21st March, 2025. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. The company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24. Revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY). The counter surged 13.62% to end at Rs 947.75 on the BSE on Friday.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Volumes spurt at Alembic Pharmaceuticals Ltd counter

Nuvoco Vistas Corporation Ltd, Jupiter Wagons Ltd, New India Assurance Company Ltd, Manappuram Finance Ltd are among the other stocks to see a surge in volumes on NSE today, 21 March 2025.Alembic Pharmaceuticals Ltd notched up volume of 19.75 lakh shares by 14:14 IST on NSE, a 19.76 fold spurt over two-week average daily volume of 99960 shares. The stock rose 13.57% to Rs.947.95. Volumes stood at 1.11 lakh shares in the last session.Nuvoco Vistas Corporation Ltd recorded volume of 22.68 lakh shares by 14:14 IST on NSE, a 18.92 times surge over two-week average daily volume of 1.20 lakh shares. The stock gained 8.53% to Rs.330.80. Volumes stood at 1.11 lakh shares in the last session.Jupiter Wagons Ltd clocked volume of 288.2 lakh shares by 14:14 IST on NSE, a 12.82 times surge over two-week average daily volume of 22.48 lakh shares. The stock gained 12.34% to Rs.352.20. Volumes stood at 24.24 lakh shares in the last session.New India Assurance Company Ltd clocked volume of 58.56 lakh shares by 14:14 IST on NSE, a 10.19 times surge over two-week average daily volume of 5.75 lakh shares. The stock gained 7.45% to Rs.164.80. Volumes stood at 6.61 lakh shares in the last session.Manappuram Finance Ltd witnessed volume of 1303.7 lakh shares by 14:14 IST on NSE, a 10.03 times surge over two-week average daily volume of 130.00 lakh shares. The stock increased 8.97% to Rs.237.02. Volumes stood at 361.59 lakh shares in the last session.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Alembic Pharma's Vadodara facility gets one Form 483 observation from US FDA

Post the conclusion of this scheduled inspection, the US FDA issued a Form 483 with one procedural observation the company's aforementioned unit. 'The company will provide comprehensive response to US FDA for the observations within the stipulated period,' Alembic Pharmaceuticals said in a statement. The announcement was made after market hours on Friday. Alembic Pharmaceuticals is in the business of the development, manufacturing, and marketing of pharmaceutical products, i.e., formulations and active pharmaceutical ingredients. The company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24. Revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY). The scrip had jumped 4.26% to end at Rs 845.65 on the BSE on Friday. Powered by Capital Market - Live

1 month agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Alembic Pharmaceuticals Ltd (APLLTD) today?

    The share price of APLLTD as on 21st April 2025 is ₹849.65. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Alembic Pharmaceuticals Ltd (APLLTD) share?

    The past returns of Alembic Pharmaceuticals Ltd (APLLTD) share are
    • Past 1 week: 0.25%
    • Past 1 month: 0.73%
    • Past 3 months: -17.51%
    • Past 6 months: -25.52%
    • Past 1 year: -10.76%
    • Past 3 years: 10.19%
    • Past 5 years: 37.49%

  3. What are the peers or stocks similar to Alembic Pharmaceuticals Ltd (APLLTD)?
  4. What is the dividend yield % of Alembic Pharmaceuticals Ltd (APLLTD) share?

    The current dividend yield of Alembic Pharmaceuticals Ltd (APLLTD) is 1.29.

  5. What is the market cap of Alembic Pharmaceuticals Ltd (APLLTD) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alembic Pharmaceuticals Ltd (APLLTD) is ₹16700.99 Cr as of 21st April 2025.

  6. What is the 52 week high and low of Alembic Pharmaceuticals Ltd (APLLTD) share?

    The 52-week high of Alembic Pharmaceuticals Ltd (APLLTD) is ₹1303.90 and the 52-week low is ₹725.20.

  7. What is the PE and PB ratio of Alembic Pharmaceuticals Ltd (APLLTD) stock?

    The P/E (price-to-earnings) ratio of Alembic Pharmaceuticals Ltd (APLLTD) is 27.12. The P/B (price-to-book) ratio is 3.47.

  8. Which sector does Alembic Pharmaceuticals Ltd (APLLTD) belong to?

    Alembic Pharmaceuticals Ltd (APLLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Alembic Pharmaceuticals Ltd (APLLTD) shares?

    You can directly buy Alembic Pharmaceuticals Ltd (APLLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.